STOCK TITAN

Trafalgar International ends Q3 with $111 in cash

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
10-Q

Rhea-AI Filing Summary

Trafalgar International, Inc. (TRFA) reported no revenue in the third quarter or first nine months of 2026. It recorded a $90,335 third-quarter net loss, versus a $36,099 loss a year earlier, and $487,667 net income for the first nine months, compared with a $669,369 loss in 2025. The nine-month profit included a $621,450 gain from debt cancellation and a $1,483 gain from cancellation of Series A preferred stock; the company said these cancellations generated no operating cash inflow and the gains were nonrecurring.

Cash was $111 at September 30, 2026, while operating activities used $96,828 in cash over nine months. Total liabilities were $102,574, down from $742,464 at December 31, 2025, after historical obligations were canceled. Management said substantial doubt about the company’s ability to continue as a going concern remains for one year after issuance and that it expects to require additional financing. Management also concluded disclosure controls were ineffective as of September 30, 2026, citing material weaknesses that include limited financial-reporting resources and insufficient segregation of duties; remediation was not complete.

1 point · 1 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

3 major · 3 points

How the balance works

Positive

  • Major pointTotal liabilities fell to $102,574 from $742,464 at December 31, 2025.

Negative

  • Major pointGoing-concern doubt remains for the one-year period after issuance.
  • Major pointDisclosure controls were ineffective as of September 30, 2026, due to material weaknesses.
  • Major pointCash was $111 at September 30, 2026, with $96,828 operating cash used.
Revenue $0 For the three and nine months ended September 30, 2026 and 2025.
Third-quarter net loss $90,335 loss Three months ended September 30, 2026; compared with a $36,099 loss in 2025.
Nine-month net income $487,667 Nine months ended September 30, 2026; compared with a $669,369 loss in 2025.
Gain on cancellation of debt $621,450 Nine months ended September 30, 2026; the gain was nonrecurring and did not generate operating cash inflows.
Cash $111 As of September 30, 2026; compared with $815 as of December 31, 2025.
Cash used in operating activities $96,828 used Nine months ended September 30, 2026; compared with $36,013 used in 2025.
Total liabilities $102,574 As of September 30, 2026; compared with $742,464 as of December 31, 2025.
substantial doubt financial
"substantial doubt about its ability to continue as a going concern"
material weaknesses financial
"material weaknesses in the Company’s internal control environment"
Material weaknesses are significant flaws in a company’s systems for ensuring its financial reports are accurate and reliable. Like a broken lock on a safe, they increase the chance that financial statements contain big errors or omissions, which can mislead investors about performance and risk; discovering one often raises questions about management oversight, may lead to restated results, and can affect investor confidence and a company’s valuation.
debt extinguishments financial
"The Company evaluates the cancellation, settlement, or extinguishment of financial obligations"
valuation allowance financial
"The Company maintains a valuation allowance against deferred tax assets"
A valuation allowance is a reserve set aside to reduce the value of certain assets on a company's financial records when there is uncertainty about whether they will generate the expected benefits. It acts like a caution sign, indicating that some assets might not be fully recoverable or worth their recorded amount. This matters to investors because it provides a more realistic picture of a company's financial health and potential risks.
fully diluted basis financial
"calculated on the fully diluted basis specified in the Amended and Restated Articles"
A fully diluted basis counts every share that could exist if all outstanding options, warrants, convertible securities and other rights were exercised or converted into common stock, showing the maximum number of shares outstanding. For investors this matters because it spreads ownership and earnings across that larger share count, like slicing a pie into every possible piece before deciding how big each investor’s slice will be, which affects per-share value and ownership percentage.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Why did TRFA report net income for the first nine months of 2026?

The main contributor was a $621,450 gain from debt cancellation; the company also recorded a $1,483 gain from canceling Series A preferred stock. Management described the gains as nonrecurring and stated that the obligation cancellations did not generate operating cash inflows.

How much cash did TRFA have at September 30, 2026?

$111 was reported as cash at September 30, 2026. The company used $96,828 in operating cash during the nine months ended that date and received $96,124 of financing cash from related-party loans.

What drove TRFA’s higher third-quarter operating expenses?

Professional services of $65,510 were recorded in third-quarter 2026, versus none in the 2025 quarter. Total operating expenses were $90,335 versus $37,412; $0 in officers’ compensation in 2026, compared with $30,000 in 2025, partly offset the professional-services cost.

What preferred-stock rights changed for TRFA after September 30, 2026?

The October 12, 2026 amended and restated Articles provide for Series A nonvoting and nonconvertible shares and Series B nonconvertible shares with at least 51% of aggregate voting power on the specified fully diluted basis. Series B shares are nonparticipating for dividends and have a $1.00-per-share liquidation preference. The Articles became effective after quarter-end.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false Q3 --12-31 0001695473 0001695473 2026-01-01 2026-09-30 0001695473 2026-11-16 0001695473 2026-09-30 0001695473 2025-12-31 0001695473 us-gaap:RelatedPartyMember 2026-09-30 0001695473 us-gaap:RelatedPartyMember 2025-12-31 0001695473 TRFA:SeriesAConvertiblePreferredStockMember 2026-09-30 0001695473 TRFA:SeriesAConvertiblePreferredStockMember 2025-12-31 0001695473 TRFA:SeriesBConvertiblePreferredStockMember 2026-09-30 0001695473 TRFA:SeriesBConvertiblePreferredStockMember 2025-12-31 0001695473 2025-01-01 2025-12-31 0001695473 2026-07-01 2026-09-30 0001695473 2025-07-01 2025-09-30 0001695473 us-gaap:ProductMember 2026-07-01 2026-09-30 0001695473 us-gaap:ProductMember 2025-07-01 2025-09-30 0001695473 TRFA:ConsultingFeesMember 2026-07-01 2026-09-30 0001695473 TRFA:ConsultingFeesMember 2025-07-01 2025-09-30 0001695473 2025-01-01 2025-09-30 0001695473 us-gaap:ProductMember 2026-01-01 2026-09-30 0001695473 us-gaap:ProductMember 2025-01-01 2025-09-30 0001695473 TRFA:ConsultingFeesMember 2026-01-01 2026-09-30 0001695473 TRFA:ConsultingFeesMember 2025-01-01 2025-09-30 0001695473 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2024-12-31 0001695473 us-gaap:CommonStockMember 2024-12-31 0001695473 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001695473 us-gaap:RetainedEarningsMember 2024-12-31 0001695473 2024-12-31 0001695473 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2025-01-01 2025-03-31 0001695473 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001695473 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0001695473 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0001695473 2025-01-01 2025-03-31 0001695473 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2025-03-31 0001695473 us-gaap:CommonStockMember 2025-03-31 0001695473 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001695473 us-gaap:RetainedEarningsMember 2025-03-31 0001695473 2025-03-31 0001695473 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2025-04-01 2025-06-30 0001695473 us-gaap:CommonStockMember 2025-04-01 2025-06-30 0001695473 us-gaap:AdditionalPaidInCapitalMember 2025-04-01 2025-06-30 0001695473 us-gaap:RetainedEarningsMember 2025-04-01 2025-06-30 0001695473 2025-04-01 2025-06-30 0001695473 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2025-06-30 0001695473 us-gaap:CommonStockMember 2025-06-30 0001695473 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0001695473 us-gaap:RetainedEarningsMember 2025-06-30 0001695473 2025-06-30 0001695473 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2025-07-01 2025-09-30 0001695473 us-gaap:CommonStockMember 2025-07-01 2025-09-30 0001695473 us-gaap:AdditionalPaidInCapitalMember 2025-07-01 2025-09-30 0001695473 us-gaap:RetainedEarningsMember 2025-07-01 2025-09-30 0001695473 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2025-09-30 0001695473 us-gaap:CommonStockMember 2025-09-30 0001695473 us-gaap:AdditionalPaidInCapitalMember 2025-09-30 0001695473 us-gaap:RetainedEarningsMember 2025-09-30 0001695473 2025-09-30 0001695473 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2025-12-31 0001695473 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2025-12-31 0001695473 us-gaap:CommonStockMember 2025-12-31 0001695473 us-gaap:AdditionalPaidInCapitalMember 2025-12-31 0001695473 us-gaap:RetainedEarningsMember 2025-12-31 0001695473 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2026-01-01 2026-03-31 0001695473 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2026-01-01 2026-03-31 0001695473 us-gaap:CommonStockMember 2026-01-01 2026-03-31 0001695473 us-gaap:AdditionalPaidInCapitalMember 2026-01-01 2026-03-31 0001695473 us-gaap:RetainedEarningsMember 2026-01-01 2026-03-31 0001695473 2026-01-01 2026-03-31 0001695473 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2026-03-31 0001695473 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2026-03-31 0001695473 us-gaap:CommonStockMember 2026-03-31 0001695473 us-gaap:AdditionalPaidInCapitalMember 2026-03-31 0001695473 us-gaap:RetainedEarningsMember 2026-03-31 0001695473 2026-03-31 0001695473 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2026-04-01 2026-06-30 0001695473 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2026-04-01 2026-06-30 0001695473 us-gaap:CommonStockMember 2026-04-01 2026-06-30 0001695473 us-gaap:AdditionalPaidInCapitalMember 2026-04-01 2026-06-30 0001695473 us-gaap:RetainedEarningsMember 2026-04-01 2026-06-30 0001695473 2026-04-01 2026-06-30 0001695473 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2026-06-30 0001695473 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2026-06-30 0001695473 us-gaap:CommonStockMember 2026-06-30 0001695473 us-gaap:AdditionalPaidInCapitalMember 2026-06-30 0001695473 us-gaap:RetainedEarningsMember 2026-06-30 0001695473 2026-06-30 0001695473 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2026-07-01 2026-09-30 0001695473 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2026-07-01 2026-09-30 0001695473 us-gaap:CommonStockMember 2026-07-01 2026-09-30 0001695473 us-gaap:AdditionalPaidInCapitalMember 2026-07-01 2026-09-30 0001695473 us-gaap:RetainedEarningsMember 2026-07-01 2026-09-30 0001695473 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2026-09-30 0001695473 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2026-09-30 0001695473 us-gaap:CommonStockMember 2026-09-30 0001695473 us-gaap:AdditionalPaidInCapitalMember 2026-09-30 0001695473 us-gaap:RetainedEarningsMember 2026-09-30 0001695473 TRFA:SeriesAConvertiblePreferredStockMember TRFA:GreenCCorporationMember 2018-07-31 2018-07-31 0001695473 TRFA:FormerShareHoldersMember TRFA:GreenCCorporationMember 2018-07-31 0001695473 TRFA:LicensingAgreementMember 2021-10-19 0001695473 TRFA:LicensingAgreementMember srt:MinimumMember 2021-10-19 2021-10-19 0001695473 TRFA:LicensingAgreementMember srt:MaximumMember 2021-10-19 2021-10-19 0001695473 TRFA:LicensingAgreementMember 2021-10-19 2021-10-19 0001695473 us-gaap:SeriesBPreferredStockMember 2025-10-16 2025-10-16 0001695473 us-gaap:SeriesBPreferredStockMember 2026-07-29 2026-07-29 0001695473 TRFA:SecondReverseSplitMember 2026-07-28 0001695473 TRFA:SecondReverseSplitMember 2026-07-29 0001695473 TRFA:SeriesBConvertiblePreferredStockMember 2025-10-16 0001695473 TRFA:KolTuvVenturesLLCMember TRFA:RightOfFirstRefusalAgreementMember TRFA:CBDMember 2020-01-30 2020-01-30 0001695473 TRFA:OntarioIncElishaKalfaAndYonahKalfaMember 2026-09-30 0001695473 TRFA:OntarioIncElishaKalfaAndYonahKalfaMember 2025-12-31 0001695473 TRFA:SigalushVenturesLLCDavidSencianesAndFernandoBiskerMember 2026-09-30 0001695473 TRFA:SigalushVenturesLLCDavidSencianesAndFernandoBiskerMember 2025-12-31 0001695473 TRFA:AitanZacharinMember 2026-09-30 0001695473 TRFA:AitanZacharinMember 2025-12-31 0001695473 TRFA:PorfirioSanchezTalaveraMember 2026-09-30 0001695473 TRFA:PorfirioSanchezTalaveraMember 2025-12-31 0001695473 TRFA:OntarioIncElishaKalfaAndYonahKalfaMember TRFA:SeriesAConvertiblePreferredStockMember 2026-01-01 2026-09-30 0001695473 TRFA:OntarioIncElishaKalfaAndYonahKalfaMember TRFA:SeriesAConvertiblePreferredStockMember 2025-01-01 2025-12-31 0001695473 TRFA:SigalushVenturesLLCDavidSencianesAndFernandoBiskerMember TRFA:SeriesAConvertiblePreferredStockMember 2026-01-01 2026-09-30 0001695473 TRFA:SigalushVenturesLLCDavidSencianesAndFernandoBiskerMember TRFA:SeriesAConvertiblePreferredStockMember 2025-01-01 2025-12-31 0001695473 TRFA:SeriesAConvertiblePreferredStockMember 2026-06-30 2026-06-30 0001695473 TRFA:SeriesAConvertiblePreferredStockMember 2026-06-30 0001695473 TRFA:SeriesBConvertiblePreferredStockMember 2025-10-22 0001695473 TRFA:SeriesBConvertiblePreferredStockMember TRFA:AitanZacharinMember 2025-10-22 0001695473 TRFA:SeriesBConvertiblePreferredStockMember srt:ChiefExecutiveOfficerMember 2025-10-22 2025-10-22 0001695473 TRFA:SeriesBConvertiblePreferredStockMember 2025-10-22 2025-10-22 0001695473 TRFA:SeriesBConvertiblePreferredStockMember TRFA:AitanZacharinMember 2026-06-29 0001695473 us-gaap:SeriesBPreferredStockMember 2026-09-17 2026-09-17 0001695473 TRFA:WarrantAMember TRFA:FirstFireGlobalOpportunitiesFundLLCMember 2021-03-31 0001695473 TRFA:GreenCCorporationMember TRFA:ExclusiveLicenseAgreementMember 2018-06-21 2018-06-21 0001695473 TRFA:PharmedicaLtdMember 2019-01-01 2019-12-31 0001695473 TRFA:GreenCCorporationMember TRFA:ExclusiveLicenseAgreementMember 2020-07-01 2020-09-30 0001695473 srt:MinimumMember TRFA:SubLicenseAgreementMember TRFA:SymtomaxUnipessoalLdaMember 2019-07-15 2019-07-15 0001695473 srt:MaximumMember TRFA:SubLicenseAgreementMember TRFA:SymtomaxUnipessoalLdaMember 2019-07-15 2019-07-15 0001695473 srt:ChiefExecutiveOfficerMember TRFA:ServicesAgreementsMember 2018-07-31 2018-07-31 0001695473 TRFA:ServicesAgreementsMember 2026-01-01 2026-09-30 0001695473 TRFA:ServicesAgreementsMember 2025-01-01 2025-09-30 0001695473 2025-06-12 2025-06-12 0001695473 us-gaap:SubsequentEventMember 2026-10-12 0001695473 us-gaap:SeriesAPreferredStockMember us-gaap:SubsequentEventMember 2026-10-12 0001695473 us-gaap:SeriesBPreferredStockMember us-gaap:SubsequentEventMember 2026-10-12 0001695473 us-gaap:SubsequentEventMember TRFA:SeriesBConvertiblePreferredStockMember 2026-10-12 2026-10-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

☒ Quarterly Report Pursuant To Section 13 or 15(d) of the Securities Exchange Act Of 1934

 

For the quarterly period ended September 30, 2026

 

☐ Transition Report Under Section 13 or 15(d) of the Securities Exchange Act Of 1934

 

For the transition period from ______________ to ______________

 

Commission File Number: 000-56027

 

TRAFALGAR INTERNATIONAL, INC.

(Exact name of registrant as specified in its charter)

 

Florida   30-0842570

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer

Identification No.)

 

200 South Biscayne Blvd Fl 20

Miami, FL 33131

(Address of principal executive offices, including Zip Code)

 

+52 1 55 6449 4966

(Issuer’s telephone number, including area code)

 

Not applicable

(Former name or former address if changed since last report)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
None   N/A   N/A

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “non-accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐ Accelerated filer ☐
Non-accelerated filer ☒ Smaller reporting company ☒
Emerging growth company ☐  

 

If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

 

State the number of shares outstanding of each of the issuer’s classes of common equity, as of the latest practicable date: 199,153 shares of common stock as of November 16, 2026.

 

 

 

 
 

 

TABLE OF CONTENTS

 

    Page
PART I FINANCIAL INFORMATION  
Item 1 Financial Statements F-2
Item 2 Management’s Discussion and Analysis of Financial Condition and Results of Operation 1
Item 3 Quantitative and Qualitative Disclosures About Market Risk 6
Item 4 Controls and Procedures 6
     
PART II OTHER INFORMATION  
Item 1 Legal Proceedings 8
Item 1A Risk Factors 8
Item 2 Unregistered Sales of equity Securities and Use of Proceeds 8
Item 3 Defaults Upon Senior Securities 8
Item 4 Mine Safety Disclosures 8
Item 5 Other Information 8
Item 6 Exhibits 8

 

i
 

 

Cautionary Note Regarding Forward Looking Statements

 

This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These statements include, without limitation, statements concerning Trafalgar International, Inc.’s (the “Company”) business strategy, future operations, financial condition, anticipated financing requirements, prospective business opportunities, development and commercialization of intellectual property, licensing arrangements, anticipated operating expenses, capital requirements, corporate restructuring activities, and other matters that are not historical facts. Forward-looking statements may be identified by words and expressions such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “project,” “seek,” “should,” “will,” “would,” and similar expressions, including the negatives of these terms. The absence of these words does not necessarily mean that a statement is not forward-looking. These statements reflect management’s current expectations, estimates, assumptions, and projections regarding future events and circumstances. Forward-looking statements are inherently subject to significant business, economic, regulatory, financial, operational, and other risks and uncertainties, many of which are beyond the Company’s control. Actual results, developments, and events may differ materially from those expressed or implied by such statements.

 

Factors that could cause actual results to differ materially from those contemplated by forward-looking statements include, but are not limited to, the following:

 

●Limited operating history under current management. The Company has recently undergone significant changes in ownership, management, corporate governance, and strategic direction. Its ability to implement its business strategy and establish sustainable operations under its current management structure remains uncertain.

 

●Limited liquidity and additional financing requirements. The Company has historically experienced operating losses and limited cash resources and may require substantial additional capital to maintain its operations, satisfy its obligations, support the development of its intellectual property, and pursue its business objectives. There can be no assurance that financing will be available when required or on commercially acceptable terms.

 

●Intellectual property and licensing arrangements. The Company’s business interests include cannabinoid-related intellectual property, technology rights, and associated licensing arrangements. The Company’s ability to preserve, enforce, develop, commercialize, or otherwise realize economic benefits from these rights may be affected by contractual obligations, intellectual property protections, third-party performance, regulatory developments, financing availability, and market conditions.

 

●Research, development, and regulatory uncertainty. The development and commercialization of cannabinoid-related therapeutic technologies may involve substantial research expenditures, clinical development requirements, regulatory approvals, and extended commercialization timelines. The Company cannot assure that any existing or proposed development program will achieve its intended objectives or obtain necessary approvals.

 

●Dependence on third parties. The Company may depend upon licensors, licensees, research institutions, development partners, consultants, service providers, and other third parties to maintain or advance certain business activities. The failure of any such party to perform its obligations could materially adversely affect the Company.

 

●Changes in corporate ownership and control. The Company has undergone significant changes in controlling ownership and management. Its future operations and strategic direction may be influenced by the decisions of its controlling shareholder and Board of Directors, and the interests of controlling shareholders may differ from those of minority shareholders.

 

●Capitalization and potential dilution. The Company has issued multiple classes of equity securities with differing voting, conversion, and other rights. Changes to its capital structure, future equity issuances, conversions, financing transactions, or amendments to the rights of outstanding securities may affect existing shareholders’ ownership percentages, voting interests, and economic rights.

 

ii
 

 

●Debt settlements and historical obligations. The Company has entered into transactions involving the compromise, cancellation, or restructuring of certain historical obligations. Disputes concerning the interpretation, enforceability, accounting treatment, or performance of these arrangements, or the identification of additional obligations, could adversely affect its financial condition and operations.

 

●Ability to identify and execute business opportunities. The Company may evaluate strategic transactions, acquisitions, investments, licensing arrangements, or other business opportunities. There can be no assurance that any such transaction will be completed, that necessary financing or approvals will be obtained, or that completed transactions will achieve anticipated results.

 

●Internal control and disclosure compliance. The Company’s limited personnel and financial resources, historical accounting practices, and changes in management may affect its ability to maintain effective disclosure controls and procedures and internal control over financial reporting. Deficiencies in these controls could adversely affect the accuracy and timeliness of its financial reporting.

 

●Regulatory and legal developments. The Company may be affected by changes in federal, state, and international laws and regulations governing securities, corporate governance, intellectual property, cannabis-derived products, pharmaceutical development, taxation, and other matters relevant to its business.

 

●Dependence on management and key personnel. The Company’s future performance may depend substantially upon the efforts, experience, relationships, and continued services of its executive officers, directors, consultants, and other key personnel.

 

●Market and economic conditions. Changes in economic conditions, capital markets, investor sentiment, interest rates, inflation, and the availability of financing may adversely affect the Company’s ability to implement its business plans and obtain necessary capital.

 

●Trading market and liquidity risks. The Company’s common stock is quoted in the over-the-counter market and may experience limited trading activity, substantial price volatility, and limited liquidity. These conditions may impair shareholders’ ability to sell their shares and may restrict the Company’s access to equity financing.

 

The foregoing factors are not exhaustive. Additional risks and uncertainties, including those described in the Company’s filings with the Securities and Exchange Commission, could cause actual results to differ materially from those anticipated in forward-looking statements.

 

Forward-looking statements speak only as of the date on which they are made. Readers should not place undue reliance on such statements. Except as required by applicable law, the Company undertakes no obligation to publicly update or revise any forward-looking statement to reflect subsequent events, circumstances, or changes in expectations.

 

The Company cannot provide assurance that any anticipated development, transaction, financing, business initiative, or other future event will occur or, if it occurs, that it will produce the results currently anticipated.

 

As used in this Quarterly Report, unless the context otherwise requires, the terms “Trafalgar,” the “Company,” “we,” “us,” and “our” refer to Trafalgar International, Inc., and, where applicable, its consolidated subsidiaries.

 

iii
 

 

TRAFALGAR INTERNATIONAL, INC.

SEPTEMBER 30, 2026

FORM 10-Q

 

INDEX

 

  Page
PART I- FINANCIAL INFORMATION  
ITEM 1. Financial Statements F-2
Consolidated Balance Sheets as of September 30, 2026 (Unaudited) and December 31, 2025 F-2
Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2026 and 2025 (Unaudited) F-3
Consolidated Statements of Stockholders’ Deficiency for the Three and Nine Months Ended September 30, 2026 and 2025 (Unaudited) F-5
Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2026 and 2025 (Unaudited) F-7
Notes to Consolidated Financial Statements (Unaudited) F-8

 

F-1
 

 

PART I- FINANCIAL INFORMATION

 

ITEM 1. FINANCIAL STATEMENTS

 

TRAFALGAR INTERNATIONAL, INC.

CONSOLIDATED BALANCE SHEETS

September 30, 2026 (unaudited) and December 31, 2025

 

   September 30,
2026
   December 31,
2025
 
   (Unaudited)     
         
ASSETS          
CURRENT ASSETS          
Cash  $111   $815 
Total current assets   111    815 
           
OTHER ASSETS          
Right of first refusal agreement cost (less accumulated amortization of $25,000 and $25,000)   -    - 
           
Total assets  $111   $815 
           
LIABILITIES AND STOCKHOLDERS’ DEFICIENCY          
           
CURRENT LIABILITIES          
Accounts payable  $16,950   $8,514 
Accrued officers’ compensation   -    470,350 
Loans payable to related parties   85,624    263,600 
Total current liabilities and total liabilities   102,574    742,464 
           
STOCKHOLDERS’ (DEFICIENCY)          
Preferred stock; 19,000,000 shares authorized, $.001 par value:
Series A Convertible Preferred-7,628,665 and 9,111,998 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively
   7,629    9,112 
Series B Convertible Preferred shares: 1,000 shares authorized, $.001 par value: 1,000 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively   1    1 
Common stock; 2,000,000,000 shares authorized, $.001 par value, as of September 30, 2026 and December 31, 2025, there are 199,153 and 189,250 shares outstanding, respectively   199    189 
Additional paid-in capital   4,393,998    4,241,006 
Accumulated deficit   (4,504,290)   (4,991,957)
           
Total stockholders’ (deficiency)   (102,463)   (741,649)
Total liabilities and stockholders’ (deficiency)  $111   $815 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

F-2
 

 

TRAFALGAR INTERNATIONAL, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

Three Months Ended September 30, 2026 and 2025 (Unaudited)

 

   September 30,
2026
   September 30,
2025
 
   (Unaudited)   (Unaudited) 
Revenue:          
Product sales  $-   $- 
Consulting fees   -    - 
Total revenue   -    - 
           
Cost of product sales   -    - 
Gross profit (loss)   -    - 
           
Operating Expenses:          
Officers compensation   -    30,000 
Professional services   65,510    - 
Other operating expenses   24,825    7,412 
Total operating expenses   90,335    37,412 
           
Income (loss) from operations   (90,335)   (37,412)
           
Other income (expenses):          
Interest expense   -    1,313 
Total other income (expenses)   -    1,313 
           
Income (loss) before provision for income taxes   (90,335)   (36,099)
Provision for income taxes   -    - 
           
Net income (loss)  $(90,335)  $(36,099)
           
Basic and diluted income (loss) per common share  $(.45)  $(.20)
Weighted average common shares outstanding-basic and diluted   199,153    180,303 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

F-3
 

 

TRAFALGAR INTERNATIONAL, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

Nine months ended September 30, 2026 and 2025 (Unaudited)

 

   September 30,
2026
   September 30,
2025
 
   (Unaudited)   (Unaudited) 
Revenue:          
Product sales  $-   $- 
Consulting fees   -    - 
Total revenue   -    - 
           
Cost of product sales   -    - 
Gross profit (loss)   -    - 
           
Operating Expenses:          
Officers compensation   30,000    90,000 
Stock-based compensation   -    1,800 
Amortization of Right of First Refusal Agreement cost   -    417 
Professional services   65,510    - 
Other operating expenses   39,756    36,982 
Total operating expenses   135,266    129,199 
           
Income (loss) from operations   (135,266)   (129,199)
           
Other income (expenses):          
Gain on cancellation of debt   621,450    - 
Gain on cancellation of preferred stock A   1,483    - 
Interest expense   -    (1,627)
Note default penalties and interest   -    (306,323)
Loss on conversion of notes payable   -    (232,220)
Total other income (expenses)   622,933    (540,170)
           
Income (loss) before provision for income taxes   487,667    (669,369)
Provision for income taxes   -    - 
           
Net income (loss)  $487,667   $(669,369)
           
Basic and diluted income (loss) per common share  $2.45   $(4.24)
Weighted average common shares outstanding-basic and diluted   199,153    157,926 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

F-4
 

 

TRAFALGAR INTERNATIONAL, INC.

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ DEFICIENCY

For the Three and Nine Months Ended September 30, 2026 and 2025

Unaudited

 

For the nine months ended  Shares   Amount   Shares   Amount   Capital   Deficit   Total 
  

Series A

       Additional         
   Preferred stock   Common Stock   Paid in   Accumulated     
For the nine months ended  Shares   Amount   Shares   Amount   Capital   Deficit   Total 
September 30, 2025:                                   
                                    
Balances at December 31, 2024   9,111,998   $9,112    107,474   $107   $3,810,853   $(4,660,345)  $(840,273)
Issuance of 22,439 common stock for notes payable conversion   -    -    22,439    22    117,978    -    118,000 
Issuance of 301 common stock for compensation   -    -    301    -    1,800    -    1,800 
Net loss for the three months ended March 31, 2025 RESTATED-Note-K   -    -    -    -    -    (242,417)   (242,417)
Balances at March 31, 2025   9,111,998   $9,112    130,214   $129   $3,930,631   $(4,902,762)  $(962,890)
                                    
Issuance of 49,754 common stock for notes payable conversion   -    -    49,754    50    271,450    -    271,500 
Issuance of 1,672 common stock for accrued compensation   -    -    1,672    1    9,999    -    10,000 
Net loss for the three months ended June 30, 2025   -    -    -    -    -    (390,853)   (390,853)
Balances at June 30, 2025   9,111,998   $9,112    181,640   $180   $4,212,080   $(5,293,615)  $(1,072,243)
                                    
Net loss for the three months ended September 30, 2025   -    -    -    -    -    (36,099)   (36,099)
Balances at September 30, 2025   9,111,998   $9,112    181,640   $180   $4,212,080   $(5,329,714)  $(1,108,342)

 

The accompanying notes are an integral part of these financial statements.

 

F-5
 

 

TRAFALGAR INTERNATIONAL, INC.

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ DEFICIENCY

Three and Nine Months Ended September 30, 2026 and 2025 (Unaudited)

 

   No. of shares   Amount   No. of shares   Amount  

No. of

shares

   Amount  

Paid in

capital

  

Retained

earnings

  

shareholders’

equity

 
  

Series A

Preferred Stock

  

Series B

Preferred Stock

   Common stock   Additional       Total 
   No. of shares   Amount   No. of shares   Amount  

No. of

shares

   Amount  

Paid in

capital

  

Retained

earnings

  

shareholders’

equity

 
Balance as of December 31, 2025   9,111,998   $9,112    1,000   $1    189,250   $189   $4,241,006   $(4,991,957)  $(741,649)
Net loss for the three months ended March 31, 2026   -    -    -    -    -    -    -    (33,376)   (33,376)
                                              
Balance as of March 31, 2026   9,111,998   $9,112    1,000   $1    189,250   $189   $4,241,006   $(5,025,333)  $(775,025)
                                              
Cancellation of preferred stock A   (9,111,998)   (9,112)   -    -    -    -    -    -    (9,112)
Issuance of preferred stock A   7,628,665    7,629    -    -    -    -    -    -    7,629 
Issuance of 9,903 common stock for   -    -    -    -    -    -    -    -      
accrued compensation   -    -    -    -    9,903    10    152,992    -    153,002 
Net income for the three months ended June 30, 2026   -    -    -    -    -    -    -    611,378    611,378 
Balance as of June 30, 2026   7,628,665   $7,629    1,000   $1    199,153   $199   $4,393,998   $(4,413,955)  $(12,128)
                                              
Net loss for the three months ended September 30, 2026   -    -    -    -    -    -    -    (90,335)   (90,335)
Balance as of September 30, 2026   7,628,665   $7,629    1,000   $1    199,153   $199   $4,393,998   $(4,504,290)  $(102,463)

 

The accompanying notes are an integral part of these financial statement

 

F-6
 

 

TRAFALGAR INTERNATIONAL, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

Nine months ended September 30, 2026 and 2025 (Unaudited)

 

   September 30,
2026
   September 30,
2025
 
   (Unaudited)   (Unaudited) 
OPERATING ACTIVITIES          
Net income (loss)  $487,667   $(669,369)
Adjustments to reconcile net income (loss) to net cash provided (used) in operating activities:          
Amortization of Right of First Refusal Agreement cost   -    417 
Issuance of common stock for compensation   -    1,800 
Issuance of common stock for accrued compensation   153,002    10,000 
Loss on conversion of notes   -    232,220 
Note default penalties and interest   -    306,323 
Gain on cancellation of debt   (621,450)   - 
Gain on cancellation of preferred stock A   (1,483)   - 
Changes in operating assets and liabilities:          
Accounts payable   8,436    970 
Accrued interest   -    1,626 
Accrued officers’ compensation   (123,000)   80,000 
Net cash used in operating activities   (96,828)   (36,013)
           
INVESTING ACTIVITIES          
Net cash used in investing activities   -    - 
           
FINANCING ACTIVITIES          
Proceeds from notes payable to related party   96,124    - 
Net cash provided by financing activities   96,124    - 
           
NET (DECREASE) IN CASH   (704)   (36,013)
           
CASH BALANCE, BEGINNING OF PERIOD   815    57,368 
           
CASH BALANCE, END OF PERIOD  $111   $21,355 
           
Supplemental Disclosures of Cash Flow Information:          
Interest paid  $-   $- 
Income tax paid  $-   $- 

 

The accompanying notes are an integral part of these consolidated financial statements

 

F-7
 

 

TRAFALGAR INTERNATIONAL, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the Nine months ended September 30, 2026 and 2025

(Unaudited)

 

NOTE A – NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Nature of Operations

 

Trafalgar International, Inc., formerly known as The Greater Cannabis Company, Inc. (the “Company” or “Trafalgar”), is a Florida corporation. The Company’s predecessor was originally organized in March 2014 as The Greater Cannabis Company, LLC and was a wholly owned subsidiary of Sylios Corp. (“Sylios”) until March 10, 2017.

 

On July 31, 2018, the Company completed a share exchange transaction pursuant to which it acquired all of the issued and outstanding Class A common shares of Green C Corporation (“Green C”), an Ontario, Canada corporation incorporated on December 21, 2017, in exchange for 9,411,998 shares of the Company’s Series A Convertible Preferred Stock (the “Exchange”).

 

Following the Exchange, the former shareholders of Green C and their designees held approximately 94% of the Company’s outstanding voting securities. Accordingly, Green C was determined to be the accounting acquirer, and the transaction was accounted for as a reverse recapitalization. The Company’s consolidated financial statements reflect the historical financial position and operating results of Green C before the Exchange and the consolidated operations of the combined entities thereafter.

 

The Exchange resulted in a change in the Company’s principal business activities. Beginning in 2018, the Company focused on the development, licensing, and commercialization of cannabinoid-related therapeutic technologies and drug delivery systems.

 

Intellectual Property and Technology Development

 

Through Green C and subsequent business arrangements, the Company pursued intellectual property and licensing opportunities involving the delivery and therapeutic application of cannabinoids. Green C previously held an exclusive worldwide license relating to an eluting transmucosal patch platform for noninvasive drug delivery in the cannabis field pursuant to a June 21, 2018 agreement with Pharmedica Ltd. The technology was intended to facilitate the absorption of active compounds through the oral mucosa. Between 2018 and approximately mid-2021, the Company concentrated on the commercialization of cannabinoid delivery technologies, including transmucosal and transdermal applications. Although the Company introduced an initial product and received limited commercial orders, management subsequently redirected its development efforts toward other therapeutic applications and licensing opportunities. The Company continues to hold interests in cannabinoid-related intellectual property and associated licensing rights. The Company’s ability to derive future economic benefits from these interests depends upon the enforceability and continuation of the applicable agreements, availability of development funding, performance of third-party collaborators, successful research and development activities, and applicable regulatory requirements.

 

Shaare Zedek Licensing and Development Arrangements

 

On October 19, 2021, the Company entered into a licensing agreement with Shaare Zedek Scientific Ltd. (“SZS”), the technology transfer organization associated with Shaare Zedek Medical Center in Jerusalem, Israel. The agreement relates to cannabinoid-based therapeutic technology intended for potential applications involving certain neurological and neuropsychiatric conditions, including autism spectrum disorder, schizophrenia, Parkinson’s disease, Alzheimer’s disease, and related disorders. In connection with the licensing arrangement, the Company also entered into a research and development arrangement involving continued development of the licensed technology and associated clinical research activities. Under the reported terms of the licensing agreement, annual licensing payments begin at $5,000 and increase by $5,000 every two calendar years, subject to a maximum annual payment of $30,000. The agreement also provides for development milestone payments of $75,000 upon initiation of a Phase II clinical trial, $200,000 upon initiation of a Phase III clinical trial, and $300,000 upon receipt of the first regulatory approval for a drug product.

 

F-8
 

 

TRAFALGAR INTERNATIONAL, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the Nine months ended September 30, 2026 and 2025

(Unaudited)

 

NOTE A – NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

 

The agreement further provides for royalties based upon specified levels of net sales of dietary supplement and pharmaceutical products, together with a sublicense royalty of 12%, subject to the applicable contractual provisions. The Company previously announced that the Israeli Ministry of Health had authorized the commencement of a Phase II clinical trial and that certain preclinical activities had been completed. As previously reported, advancement of the clinical program has depended upon obtaining specialized active pharmaceutical ingredients, securing additional development financing, and satisfying applicable research and regulatory requirements. The Company has historically reported that certain annual licensing payments were placed on hold while the specialized ingredients necessary for clinical development were being sourced. No assurance can be given that the development program will proceed according to any anticipated timetable, that additional funding will become available, or that any product utilizing the licensed technology will receive regulatory approval or achieve commercial success.

 

Historical Capital Restructuring

 

Effective October 16, 2025, the Company implemented a 1-for-1,500 reverse split of its outstanding common stock pursuant to an amendment to its Articles of Incorporation filed with the Florida Department of State.

 

On July 29, 2026, the Company’s Board of Directors approved, and the Company filed with the Florida Department of State, Articles of Amendment to its Articles of Incorporation to (i) change the Company’s name from The Greater Cannabis Company, Inc. to Trafalgar International, Inc. and (ii) effect a 1-for-5 reverse split of its outstanding common stock (the “Second Reverse Split”). The name change and the Second Reverse Split became effective in the market on September 17, 2026, following processing by the Financial Industry Regulatory Authority (“FINRA”). Fractional shares resulting from the Second Reverse Split were rounded up to the next whole share. The Second Reverse Split did not change the number of authorized shares of common stock or preferred stock, the par value of the common stock, or the number of outstanding shares of preferred stock. As a result of the Second Reverse Split, the number of issued and outstanding shares of common stock was reduced from 994,379 shares to 199,153 shares, including whole shares issued in lieu of fractional shares. The Company’s common stock traded under the symbol “GCAND” following the Second Reverse Split and began trading under the symbol “TRFA” on October 21, 2026.

 

All common share amounts, common stock and additional paid-in capital amounts, weighted average shares outstanding, and per share amounts in the accompanying consolidated financial statements and these notes have been retroactively adjusted to reflect the Second Reverse Split for all periods presented, except where otherwise indicated.

 

The Company also established a class of Series B Convertible Preferred Stock consisting of 1,000 designated shares.

 

The Company’s outstanding preferred securities have historically included Series A Convertible Preferred Stock and Series B Convertible Preferred Stock, each governed by the applicable certificate of designation and amendments thereto. The historical conversion and voting provisions of these securities, together with subsequent transfers, cancellations, issuances, and the amendment and restatement of the Company’s Articles of Incorporation following September 30, 2026, are addressed in the accompanying notes concerning stockholders’ equity and subsequent events.

 

F-9
 

 

TRAFALGAR INTERNATIONAL, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the Nine months ended September 30, 2026 and 2025

(Unaudited)

 

NOTE A – NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

 

June 2026 Change of Control and Corporate Reorganization

 

On June 29, 2026, Trafalgar Asset Management, LLC entered into transactions pursuant to which it acquired the Company’s outstanding Series A Preferred Stock and Series B Preferred Stock from the prior holders. These transactions resulted in a significant change in the Company’s ownership and governance structure. Trafalgar Asset Management, LLC became the holder of the outstanding preferred securities and acquired the rights associated with those securities under their governing instruments, subject to the terms and limitations of the applicable certificates of designation. The Company’s historical Series A Preferred Stock carried voting and conversion rights, while the Series B Preferred Stock was designed to provide significant voting control. The precise voting rights applicable following the June 2026 transfers depend upon the governing instruments and the effect of their transfer provisions. In connection with the change of control, the Company also entered into debt cancellation and release agreements with certain creditors pursuant to which specified historical indebtedness was compromised, settled, canceled, or otherwise extinguished. The financial effects of these transactions, including the recognition of any gains, equity adjustments, or related-party accounting consequences, are reflected in the accompanying consolidated financial statements to the extent required by generally accepted accounting principles in the United States (“U.S. GAAP”). Following the change of control, the Company implemented changes to its executive management and Board of Directors. On July 29, 2026, the Board of Directors appointed Carlos Septién Michel as Chief Operating Officer, Michelle Cervantes Vivanco as Chief Financial Officer, and Ernesto Gómez Berjón as Chief Growth Officer, and appointed each of them to the Board of Directors. Effective September 18, 2026, Mr. Septién was appointed Chief Executive Officer and resigned as Chief Operating Officer, and Porfirio Sanchez Talavera resigned as Chief Executive Officer. As of September 30, 2026, the Company’s management and governance structure included Porfirio Sanchez Talavera as Chairman of the Board of Directors, Carlos Septién Michel as Chief Executive Officer, Michelle Cervantes Vivanco as Chief Financial Officer, and Ernesto Gómez Berjón as Chief Growth Officer. The Company’s Board of Directors included Porfirio Sanchez Talavera, Carlos Septién Michel, Michelle Cervantes Vivanco, and Ernesto Gómez Berjón.

 

Business Strategy

 

Following the June 2026 change of control, management began evaluating the Company’s existing business interests, capital structure, historical obligations, and potential strategic opportunities.

 

The Company continues to maintain its interests in cannabinoid-related intellectual property and licensing arrangements while evaluating opportunities to develop, commercialize, restructure, or otherwise realize value from its existing assets and pursue additional business activities. The Company’s ability to implement its business strategy will depend upon, among other matters, its financial resources, contractual obligations, access to additional capital, applicable regulatory requirements, and the successful execution of any future transactions.

 

Principles of Consolidation

 

The accompanying consolidated financial statements include the accounts of Trafalgar International, Inc. and its wholly owned subsidiary, Biocanrx, Inc. All significant intercompany balances and transactions have been eliminated in consolidation.

 

Basis of Presentation and Interim Financial Statements

 

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and the applicable rules and regulations of the Securities and Exchange Commission (“SEC”), including the requirements of Form 10-Q and Regulation S-X. Accordingly, these financial statements do not include all of the information and disclosures required by U.S. GAAP for complete annual financial statements. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and accompanying notes included in its Annual Report on Form 10-K for the year ended December 31, 2025. In the opinion of management, the accompanying financial statements include all adjustments necessary to present fairly, in all material respects, the Company’s consolidated financial position as of September 30, 2026, and its consolidated results of operations, changes in stockholders’ equity (deficiency), and cash flows for the periods presented. Such adjustments consist of normal recurring adjustments and any other adjustments required for a fair presentation of the interim financial statements. The results of operations for the three and nine months ended September 30, 2026 are not necessarily indicative of the results that may be expected for the full fiscal year ending December 31, 2026.

 

F-10
 

 

TRAFALGAR INTERNATIONAL, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the Nine months ended September 30, 2026 and 2025

(Unaudited)

 

NOTE A – NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

 

Cash and Cash Equivalents

 

The Company considers all highly liquid investments with original maturities of three months or less when acquired to be cash equivalents. Cash and cash equivalents are carried at amounts that approximate fair value because of their short-term nature. Cash balances may be maintained at financial institutions and may, from time to time, exceed applicable deposit insurance limits.

 

Accounts Receivable and Credit Losses

 

The Company recognizes trade and other receivables at the amounts expected to be collected, net of an allowance for expected credit losses, when applicable. The Company evaluates expected credit losses in accordance with Accounting Standards Codification (“ASC”) Topic 326, Financial Instruments—Credit Losses. The evaluation considers relevant historical collection experience, current conditions, and reasonable and supportable forecasts affecting the collectibility of financial assets within the scope of the standard. Receivables determined to be uncollectible are written off against the applicable allowance. Recoveries of amounts previously written off are recognized when received or otherwise realized.

 

Use of Estimates

 

The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions affecting the amounts reported in the financial statements and accompanying disclosures. Significant estimates and judgments may include the valuation and recoverability of intangible assets and contractual rights, recognition and measurement of liabilities, accounting for debt extinguishments and settlements, valuation of equity instruments, assessment of embedded conversion features and derivative instruments, income taxes, and the evaluation of contingencies. Management evaluates its estimates using information available as of the financial statement reporting date. Actual results could differ materially from those estimates.

 

Fair Value of Financial Instruments

 

The Company applies ASC Topic 820, Fair Value Measurement, when measuring the fair value of financial assets, financial liabilities, and other items for which fair value measurement is required or permitted under U.S. GAAP. Fair value represents the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC 820 establishes a three-level hierarchy for the inputs used in valuation techniques:

 

●Level 1: Unadjusted quoted prices in active markets for identical assets or liabilities.

 

●Level 2: Observable inputs other than Level 1 quoted prices, including quoted prices for similar assets or liabilities and other market-corroborated inputs.

 

●Level 3: Significant unobservable inputs reflecting assumptions that market participants would use in pricing the asset or liability.

 

The Company uses valuation techniques appropriate to the circumstances and for which sufficient information is available, maximizing observable inputs and minimizing unobservable inputs. The carrying amounts of certain short-term financial instruments, including cash, accounts payable, accrued expenses, and certain short-term borrowings, may approximate their fair values because of their relatively short maturities. Financial instruments with significant conversion, settlement, or other contractual features are evaluated separately under the applicable accounting guidance.

 

F-11
 

 

TRAFALGAR INTERNATIONAL, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the Nine months ended September 30, 2026 and 2025

(Unaudited)

 

NOTE A – NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

 

Convertible Securities and Derivative Instruments

 

The Company evaluates its convertible debt instruments, preferred stock, warrants, options, and other equity-linked financial instruments to determine their appropriate classification and accounting treatment under applicable U.S. GAAP, including ASC Topics 480 and 815 and the relevant provisions of ASC Topic 470. This evaluation includes consideration of whether an instrument or embedded contractual feature requires liability classification, bifurcation, or separate measurement at fair value. Instruments or features classified as derivative liabilities are initially recognized at fair value and subsequently remeasured at each applicable reporting date, with changes in fair value recognized in earnings unless otherwise required by U.S. GAAP. Instruments classified within permanent or temporary equity are accounted for in accordance with the applicable recognition, measurement, and presentation requirements. The Company evaluates modifications, conversions, extinguishments, and cancellations of financial instruments based on the substance and contractual terms of each transaction.

 

Intangible Assets and Impairment

 

The Company evaluates its intangible assets, intellectual property interests, licensing rights, and other long-lived assets under the applicable provisions of ASC Topic 350, Intangibles—Goodwill and Other, and ASC Topic 360, Property, Plant, and Equipment. Finite-lived intangible assets are amortized over their estimated useful lives when applicable. Long-lived assets subject to amortization are reviewed for impairment when events or changes in circumstances indicate that their carrying amounts may not be recoverable. Recoverability is generally assessed by comparing the carrying amount of the applicable asset or asset group with the undiscounted future cash flows expected to result from its use and eventual disposition. If the carrying amount is not recoverable, an impairment loss is measured in accordance with the applicable accounting guidance. The Company also considers whether contractual rights have expired, been terminated, become unenforceable, or otherwise experienced changes affecting their recognition, measurement, or recoverability.

 

Stock-Based Compensation and Equity Instruments Issued for Services

 

The Company accounts for share-based payment arrangements under ASC Topic 718, Compensation—Stock Compensation, including applicable arrangements with employees and nonemployees. The cost of equity-classified share-based awards is generally measured based on grant-date fair value and recognized over the period in which the related services are provided or the applicable vesting conditions are satisfied. Liability-classified awards are measured and remeasured in accordance with the applicable provisions of ASC 718. Equity instruments issued in settlement of accrued compensation, accounts payable, or other obligations are evaluated based upon the substance of the underlying arrangement and the accounting guidance applicable to the original obligation and settlement transaction.

 

Related-Party Transactions

 

The Company identifies and evaluates related-party relationships and transactions in accordance with ASC Topic 850, Related Party Disclosures, and other applicable accounting guidance. Related parties may include principal shareholders, directors, executive officers, entities under common control, and other persons or entities capable of exercising significant influence over the Company’s financial or operating decisions. Transactions with related parties are recognized and measured under the applicable accounting guidance and disclosed when required, including the nature of the relationship, a description of the transaction, the amounts involved, and outstanding balances or commitments. Debt cancellations, contributions, settlements, and other transactions involving shareholders or entities under common control are evaluated to determine whether their economic substance requires recognition in earnings, equity, or another financial statement classification.

 

F-12
 

 

TRAFALGAR INTERNATIONAL, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the Nine months ended September 30, 2026 and 2025

(Unaudited)

 

NOTE A – NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

 

Revenue Recognition

 

The Company recognizes revenue from contracts with customers in accordance with ASC Topic 606, Revenue from Contracts with Customers. Under ASC 606, revenue is recognized when control of promised goods or services is transferred to a customer in an amount reflecting the consideration to which the Company expects to be entitled in exchange for those goods or services. The Company applies the five-step revenue recognition model by identifying the contract with the customer, identifying the performance obligations, determining the transaction price, allocating the transaction price to the performance obligations, and recognizing revenue as the applicable obligations are satisfied. Revenue from product sales is generally recognized when control of the products transfers to the customer. Revenue arising from licensing arrangements, if any, is evaluated based on the nature of the intellectual property rights granted, the contractual performance obligations, and the applicable recognition requirements of ASC 606. The Company separately evaluates whether amounts arising from arrangements outside the scope of ASC 606 should be recognized under other applicable accounting guidance.

 

Advertising and Promotional Expenses

 

Advertising and promotional expenditures are generally expensed as incurred, except when a different accounting treatment is required under applicable U.S. GAAP.

 

Income Taxes

 

The Company accounts for income taxes under ASC Topic 740, Income Taxes, using the asset and liability method. Deferred income tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities, as well as operating loss and tax credit carryforwards, as applicable. Deferred tax assets are reduced by a valuation allowance when, based on the available evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. The Company recognizes the financial statement effects of uncertain tax positions when the applicable recognition and measurement criteria under ASC 740 are satisfied. Income tax expense or benefit for interim periods is determined in accordance with the applicable interim reporting provisions of ASC 740, including the estimated annual effective tax rate methodology and the separate recognition of discrete items when required.

 

Net Income (Loss) Per Common Share

 

The Company calculates basic and diluted net income (loss) per common share in accordance with ASC Topic 260, Earnings Per Share. Basic net income (loss) per common share is calculated by dividing net income (loss) attributable to common shareholders by the weighted-average number of common shares outstanding during the applicable period.

 

Diluted net income (loss) per common share reflects the potential dilution that could occur if securities or other contracts to issue common stock were converted, exercised, or otherwise settled in common shares, to the extent their inclusion would be dilutive. Potentially dilutive instruments may include convertible preferred stock, convertible debt, warrants, options, and other equity-linked securities. The Company evaluates the applicable conversion provisions, participating rights, contractual limitations, and effective dates of outstanding instruments in determining the appropriate basic and diluted earnings-per-share calculations. Potential common shares are excluded from diluted earnings per share when their inclusion would be antidilutive.

 

F-13
 

 

TRAFALGAR INTERNATIONAL, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the Nine months ended September 30, 2026 and 2025

(Unaudited)

 

NOTE A – NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

 

Recently Adopted and Issued Accounting Standards

 

The Company evaluates accounting standards updates issued by the Financial Accounting Standards Board to determine their applicability and potential effects on the Company’s consolidated financial statements. Accounting standards that became effective in prior reporting periods are reflected in the Company’s accounting policies to the extent applicable. The Company will disclose newly adopted accounting standards and recently issued standards not yet effective when their adoption has had, or is reasonably expected to have, a material effect on its financial position, results of operations, cash flows, or related disclosures.

 

NOTE B - GOING CONCERN

 

The accompanying unaudited condensed consolidated financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business.

 

In accordance with Accounting Standards Codification (“ASC”) Topic 205-40, *Presentation of Financial Statements—Going Concern*, management evaluates whether conditions and events, considered in the aggregate, raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date the financial statements are issued.

 

The Company has historically experienced operating losses, negative cash flows from operations, limited liquidity, and a working capital deficiency. These conditions, together with the Company’s continuing operating expenses, outstanding obligations, and anticipated funding requirements, raise substantial doubt about its ability to continue as a going concern.

 

Management’s plans include seeking additional financing, evaluating strategic transactions, reducing or restructuring outstanding obligations where appropriate, and pursuing opportunities to develop or realize value from the Company’s existing intellectual property and licensing arrangements.

 

The Company’s ability to execute these plans depends upon factors that include the availability of financing, creditor cooperation, the performance of third parties, and general business and market conditions. Management cannot assure that sufficient funding will be available or that the Company’s plans will be successfully implemented.

 

After considering management’s plans and the uncertainties associated with their implementation, management has concluded that substantial doubt about the Company’s ability to continue as a going concern has not been alleviated and continues to exist for the one-year period following the issuance date of these financial statements.

 

The accompanying unaudited condensed consolidated financial statements do not include adjustments that might result from the outcome of this uncertainty.

 

NOTE C – RIGHT OF FIRST REFUSAL AGREEMENT

 

On January 30, 2020, the Company entered into a Right of First Refusal Agreement with Kol Tuv Ventures, LLC (“KTV”), an entity engaged in the cosmetics, health, and wellness industries. Under the agreement, the Company paid KTV $25,000 in consideration for an exclusive right of first refusal to participate in certain cannabidiol (“CBD”) business opportunities pursued by KTV. The agreement also contemplated potential additional investments or payments associated with the development or acquisition of qualifying opportunities. The agreement provided for a five-year term, and the initial $25,000 payment was amortized over that period. The contractual term expired in January 2025. The $25,000 payment has been fully amortized, and no carrying value associated with the agreement remains in the Company’s consolidated financial statements.

 

F-14
 

 

TRAFALGAR INTERNATIONAL, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the Nine months ended September 30, 2026 and 2025

(Unaudited)

 

NOTE D - LOANS PAYABLE TO RELATED PARTIES

 

The Company has historically received financing from certain shareholders, officers, and other related parties to support its operations. Loans payable to related parties consisted of the following:

 

   September 30, 2026   December 31, 2025 
02490585 Ontario Inc. (Elisha Kalfa) and Yonah Kalfa, former holders of a total of 2,966,666 shares of Series A Convertible Preferred Stock  $–   $180,000 
Sigalush Ventures LLC (David Sencianes) and Fernando Bisker, former holders of a total of 2,966,666 shares of Series A Convertible Preferred Stock   –    80,000 
Aitan Zacharin, former Chief Executive Officer   –    3,600 
Porfirio Sanchez Talavera, Chairman   85,624    – 
Total  $85,624   $263,600 

 

The loans outstanding at December 31, 2025 originated under arrangements entered into in connection with the Company’s July 31, 2018 share exchange and related transactions. Under the reported terms of the applicable agreements, the loans were non-interest-bearing and contemplated repayment following specified financing or revenue events, subject to additional maturity and conversion provisions. In connection with the Company’s change of control, the Company entered into Debt Cancellation and Release Agreements, effective June 30, 2026, with (i) 02490585 Ontario Inc. (Elisha Kalfa) and Yonah Kalfa, and (ii) Sigalush Ventures LLC (David Sencianes) and Fernando Bisker, under which the holders irrevocably canceled, released, and discharged loans of $180,000 and $80,000, respectively, including all accrued and unpaid amounts. Effective June 29, 2026, Aitan Zacharin, the Company’s former Chief Executive Officer, released all related-party indebtedness owed to him by the Company. The cancellation of related-party loans, together with the cancellation of accrued officers’ compensation described in Note I, resulted in a gain on cancellation of debt of $621,450 for the nine months ended September 30, 2026.

 

During the nine months ended September 30, 2026, Porfirio Sanchez Talavera, the Company’s Chairman and, until September 18, 2026, its Chief Executive Officer, made payments on behalf of the Company to fund its operating expenses. These amounts are non-interest-bearing and have no stated maturity. As of September 30, 2026, loans payable to related parties totaled $85,624, all of which was owed to Mr. Sanchez Talavera.

 

NOTE E - NOTES PAYABLE TO THIRD PARTIES

 

The Company had no notes payable to third parties outstanding at September 30, 2026 or December 31, 2025.

 

NOTE F - DERIVATIVE LIABILITIES

 

The Company has historically issued convertible promissory notes and other equity-linked instruments containing conversion or exercise provisions that required evaluation under Accounting Standards Codification (“ASC”) Topic 815, Derivatives and Hedging. In connection with its historical financing arrangements with FirstFire Global Opportunities Fund, LLC (“FirstFire”), the Company previously recognized derivative liabilities associated with certain conversion features of its convertible promissory notes. As previously reported, the derivative liability associated with these instruments was reduced to zero during 2021 following changes to the applicable conversion provisions. The FirstFire convertible promissory note was subsequently fully satisfied and extinguished pursuant to the June 12, 2025 amendment and modification agreement and the completion of the Company’s October 16, 2025 reverse stock split, as described in Note E. The Company reported no derivative liabilities as of December 31, 2025 or September 30, 2026.

 

F-15
 

 

TRAFALGAR INTERNATIONAL, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the Nine months ended September 30, 2026 and 2025

(Unaudited)

 

NOTE G — CAPITAL STOCK AND WARRANTS

 

Authorized Capital Stock

 

The Company’s capital structure consists of common stock and preferred stock, each having a par value of $0.001 per share. The Company has historically authorized 2,000,000,000 shares of common stock and 19,000,000 shares of preferred stock, including shares designated as Series A Convertible Preferred Stock and Series B Convertible Preferred Stock. The rights, preferences, privileges, and limitations of each class or series are governed by the Company’s Articles of Incorporation, as amended, and the applicable certificates of designation.

 

Series A Convertible Preferred Stock

 

On July 31, 2018, the Company issued 9,411,998 shares of Series A Convertible Preferred Stock in connection with its acquisition of Green C Corporation. Under the historical terms of the Series A Preferred Stock, each share was convertible into 50 shares of common stock and entitled its holder to 1.76 votes per share on matters submitted to the Company’s shareholders, subject to the applicable governing instruments. During subsequent periods, certain shares of Series A Preferred Stock were converted, canceled, or otherwise affected by corporate transactions. In connection with the June 2026 change-of-control transactions, the Company canceled 9,111,998 previously outstanding Series A Preferred Shares and issued 7,628,665 Series A Preferred Shares pursuant to the applicable restructuring arrangements. As of September 30, 2026, the Company reported 7,628,665 shares of Series A Preferred Stock issued and outstanding, all held by Trafalgar Asset Management, LLC.

 

Series B Convertible Preferred Stock

 

On October 22, 2025, the Company filed Articles of Amendment to its Articles of Incorporation with the Florida Department of State establishing a series of 1,000 shares of Series B Convertible Preferred Stock, par value $0.001 per share. On the same date, the Company issued all 1,000 Series B Preferred Shares to Aitan Zacharin, its then-Chief Executive Officer and sole director, in consideration of the waiver of $20,000 in accrued compensation. Under the original Series B designation, the outstanding Series B Preferred Shares collectively were entitled to 51% of the Company’s voting power, subject to specified limitations and termination provisions. The designation also provided for conversion into common stock at an initial rate of 100,000 shares of common stock per Series B Preferred Share, subject to adjustment under the governing instrument. The Series B designation included a provision terminating the enhanced voting rights upon certain transfers of Series B Preferred Shares to third parties, other than transfers pursuant to the laws of descent and distribution. Following such a transfer, the shares were to vote on an as-converted basis in accordance with the designation.

 

On June 29, 2026, Trafalgar Asset Management, LLC acquired all 1,000 outstanding Series B Preferred Shares from Mr. Zacharin in connection with the Company’s change of control.

 

As of September 30, 2026, Trafalgar Asset Management, LLC held all outstanding Series B Preferred Shares. Under the Series B designation then in effect, the transfer of these shares was subject to provisions affecting the continuation of the enhanced voting rights originally associated with the Series B Preferred Stock. The voting rights applicable following the transfer are determined in accordance with those provisions, including the designation’s requirements concerning voting on an as-converted basis following specified transfers.

 

The Series B Preferred Shares do not provide for ordinary dividends and carry the liquidation rights established in the applicable designation. Subsequent amendments to the rights and preferences of the Company’s preferred securities are addressed in Note K, Subsequent Events.

 

F-16
 

 

TRAFALGAR INTERNATIONAL, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the Nine months ended September 30, 2026 and 2025

(Unaudited)

 

NOTE G — CAPITAL STOCK AND WARRANTS (continued)

 

Common Stock

 

The Company’s common stock has a par value of $0.001 per share. Each outstanding share of common stock is entitled to one vote on matters submitted to common shareholders, subject to the voting rights of outstanding preferred securities and applicable law.

 

Effective October 16, 2025, the Company implemented a 1-for-1,500 reverse stock split of its outstanding common stock. The reverse stock split reduced the number of issued and outstanding common shares without changing the authorized number of common shares or their par value. Fractional share interests were treated in accordance with the applicable corporate action.

 

Effective September 17, 2026, the Company implemented a 1-for-5 reverse split of its outstanding common stock, which reduced the number of issued and outstanding shares of common stock from 994,379 shares to 199,153 shares, including whole shares issued in lieu of fractional shares. Share and per share amounts have been retroactively adjusted to reflect the Second Reverse Split, as described in Note A.

 

In October 2025, the Company also reported the issuance of 44,679 shares of common stock in connection with a historical conversion of indebtedness owed to FirstFire.

 

During the second quarter of 2026, the Company issued 9,903 shares of common stock (49,444 shares prior to giving effect to the Second Reverse Split) in satisfaction of previously accrued compensation, with a reported value of $153,002.

 

As of September 30, 2026, the Company reported 199,153 shares of common stock issued and outstanding.

 

Change of Control

 

On June 29, 2026, Trafalgar Asset Management, LLC, an entity owned and controlled by Porfirio Sanchez Talavera, acquired the outstanding Series A Preferred Stock and Series B Preferred Stock pursuant to privately negotiated transactions. The acquisition of the preferred securities resulted in a change in the Company’s controlling shareholder and was accompanied by changes in executive management and the Board of Directors. The voting and conversion rights associated with the transferred preferred securities remained governed by the applicable designations in effect at the time of the transactions, including any transfer-related limitations. Subsequent amendments to the Company’s capital structure and preferred-stock rights are described in Note K, Subsequent Events.

 

Warrants

 

In March 2021, in connection with its FirstFire financing, the Company issued three warrants designated Warrant A, Warrant B, and Warrant C. The warrants originally entitled FirstFire to purchase an aggregate of 50,000,000 shares of the Company’s common stock at specified exercise prices, subject to their contractual terms. The Company previously reported an aggregate initial valuation of $262,429 for these warrants. Each of the warrants expired by its terms on September 11, 2022.

 

As of September 30, 2026, the Company had no outstanding warrants.

 

NOTE H - INCOME TAXES

 

The Company accounts for income taxes in accordance with Accounting Standards Codification (“ASC”) Topic 740, Income Taxes. The Company and its United States subsidiaries file federal income tax returns, and its Canadian subsidiary, Green C Corporation, has historically been subject to applicable Canadian federal and Ontario provincial income tax reporting requirements.

 

F-17
 

 

TRAFALGAR INTERNATIONAL, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the Nine months ended September 30, 2026 and 2025

(Unaudited)

 

NOTE H - INCOME TAXES (continued)

 

The Company has incurred cumulative operating losses and has historically generated net operating loss carryforwards that may be available to offset future taxable income, subject to applicable statutory limitations.

 

Deferred income tax assets are recognized for deductible temporary differences and available tax loss carryforwards. The Company maintains a valuation allowance against deferred tax assets to the extent management determines that realization of the associated tax benefits is not more likely than not.

 

Based upon the Company’s historical operating results, cumulative losses, limited revenue-generating activities, and uncertainty concerning future taxable income, the Company has historically maintained a full valuation allowance against its deferred tax assets.

 

The Company’s ability to utilize its federal net operating loss carryforwards and certain other tax attributes may be subject to limitations under Sections 382 and 383 of the Internal Revenue Code. These provisions generally restrict the utilization of certain tax attributes following specified changes in corporate ownership. The Company’s June 2026 change-of-control transactions, together with other historical changes in equity ownership, may result in limitations on the utilization of its existing tax attributes. Accordingly, the existence of net operating loss carryforwards does not assure that such amounts will be available to offset future taxable income.

 

The Company evaluates uncertain tax positions in accordance with ASC 740 and recognizes tax benefits only when the applicable recognition and measurement requirements are satisfied.

 

The Company’s tax returns remain subject to examination by applicable taxing authorities for the periods permitted under relevant statutes of limitation, including periods for which net operating loss carryforwards may be examined in connection with their utilization.

 

NOTE I - COMMITMENTS AND CONTINGENCIES

 

Pharmedica Exclusive License Agreement

 

On June 21, 2018, Green C Corporation entered into an exclusive license agreement with Pharmedica Ltd. (“Pharmedica”), an Israeli company, relating to certain intellectual property associated with transmucosal delivery technology for medicinal and recreational cannabis products. The agreement required an initial license payment of $100,000, which was paid by an entity affiliated with Green C’s then-management, and contemplated royalties equal to 5% of net sales of licensed products, subject to a minimum annual royalty of $50,000. The Company generated limited revenues from the licensed technology and did not satisfy the first minimum annual royalty payment. As a result, the Company recognized an impairment charge of $69,749 during the year ended December 31, 2019, reducing the remaining carrying value of the licensed intangible asset to zero. On September 2, 2020, Green C notified Pharmedica of its intention to terminate the license agreement. On September 17, 2020, Pharmedica accepted the proposed termination and indicated that it would not seek to impose further obligations upon Green C. In connection with the termination, the Company recognized forgiveness of accrued royalties totaling $50,000 during the third quarter of 2020. The Pharmedica licensing arrangement was terminated in 2020, and the Company has historically reported no remaining intangible asset or accrued royalty liability associated with the agreement.

 

Symtomax Sub-License Agreement

 

On July 15, 2019, the Company entered into a sublicense agreement with Symtomax Unipessoal Lda (“Symtomax”), granting certain nonexclusive rights to use Company technology and intellectual property for the development and commercialization of products in Europe, the Middle East, and Africa. The agreement contemplated royalty payments to the Company ranging from 10% to 17% of qualifying sales. On May 27, 2020, the parties entered into an amended and restated sublicense agreement. The amended agreement provided for a term ending August 31, 2021, or earlier upon the cessation of commercialization activities, with certain potential country-specific extensions based upon specified royalty thresholds. The Company has historically reported that Symtomax did not generate sales requiring royalty payments under the agreement. No material royalty revenue or receivable associated with the Symtomax arrangement has been reported in the periods presented.

 

F-18
 

 

TRAFALGAR INTERNATIONAL, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the Nine months ended September 30, 2026 and 2025

(Unaudited)

 

NOTE I - COMMITMENTS AND CONTINGENCIES (continued)

 

Shaare Zedek Licensing and Development Arrangements

 

On October 19, 2021, the Company entered into a licensing agreement with Shaare Zedek Scientific Ltd. (“SZS”), the technology transfer organization associated with Shaare Zedek Medical Center in Jerusalem, Israel, relating to certain cannabinoid-based therapeutic technologies. The Company also entered into associated research and development arrangements concerning the continued development and potential clinical evaluation of the licensed technology.

 

Under the reported terms of the licensing agreement, annual licensing payments commence at $5,000 and increase by $5,000 every two calendar years, subject to a maximum annual payment of $30,000. The agreement also provides for milestone payments of $75,000 upon initiation of a Phase II clinical trial, $200,000 upon initiation of a Phase III clinical trial, and $300,000 upon receipt of the first regulatory approval for a drug product.

 

The agreement further provides for royalties based upon specified levels of net sales of qualifying products and a sublicense royalty of 12%, subject to the applicable contractual provisions.

 

The Company previously reported that certain annual licensing payments were placed on hold while specialized ingredients necessary for clinical development were being sourced. The timing and amount of future payments under

 

the arrangement depend upon the continuing contractual obligations, applicable development milestones, and any modifications or accommodations agreed upon by the parties.

 

The Company has not generated material commercial revenue from the licensed technology. Continued development and potential commercialization will require additional funding and remain subject to scientific, regulatory, contractual, and operational uncertainties.

 

Employment and Compensation Arrangements

 

The Company has historically entered into employment, consulting, and other service arrangements with executive officers and other service providers. Certain historical compensation obligations were settled through the issuance of equity securities or were canceled or released in connection with the Company’s June 2026 restructuring and change-of-control transactions. The Company recognizes compensation expense and related liabilities in accordance with the applicable terms of its service arrangements and U.S. GAAP.

 

On July 31, 2018, the Company entered into a Services Agreement with Aitan Zacharin, its then Chief Executive Officer, providing for a monthly base salary of $10,000. The Company expensed $30,000 and $90,000 under the Services Agreement for the nine months ended September 30, 2026 and 2025, respectively. In connection with the change of control on June 29, 2026, Mr. Zacharin resigned from all officer positions, and no compensation has accrued under the Services Agreement for any period after that date. Accrued officers’ compensation of $470,350 at December 31, 2025 was eliminated during the nine months ended September 30, 2026 through the issuance of common stock for accrued compensation (see Note G) and the Debt Cancellation and Release Agreements (see Note D). As of September 30, 2026, the Company had no accrued officers’ compensation, and none of the Company’s current officers receives compensation from the Company.

 

F-19
 

 

TRAFALGAR INTERNATIONAL, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the Nine months ended September 30, 2026 and 2025

(Unaudited)

 

NOTE I - COMMITMENTS AND CONTINGENCIES (continued)

 

Other Commitments and Contingencies

 

The Company evaluates contractual commitments, threatened or pending claims, and other contingencies in accordance with ASC Topic 450, Contingencies, and other applicable accounting guidance. Loss contingencies are accrued when a loss is probable and reasonably estimable. Material contingencies that do not meet the criteria for accrual are disclosed when required under U.S. GAAP. The Company’s material historical licensing arrangements and related contractual commitments are described above and, where applicable, in Note A, Nature of Operations and Summary of Significant Accounting Policies.

 

NOTE J-RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS

 

The Company previously restated its consolidated financial statements for the three months ended March 31, 2025, originally included in its Quarterly Report on Form 10-Q filed on May 12, 2025, to correct the accounting treatment of certain obligations arising under its convertible promissory note with FirstFire Global Opportunities Fund, LLC (“FirstFire”). The restatement included recognition of additional default interest and penalties totaling $138,906 as of March 31, 2025, based upon the applicable contractual provisions. On June 12, 2025, the Company and FirstFire entered into an amendment and modification agreement addressing the outstanding note obligations and providing for their full satisfaction and extinguishment upon completion of the Company’s contemplated 1-for-1,500 reverse stock split. The Company completed the reverse stock split effective October 16, 2025. Pursuant to the amendment, the FirstFire note was fully satisfied and extinguished, and the Company’s remaining obligations under the note were discharged, as further described in Note E. The historical restatement relates to the accounting treatment of obligations existing as of March 31, 2025, and does not represent indebtedness remaining outstanding as of September 30, 2026.

 

NOTE K – SUBSEQUENT EVENTS

 

The Company has evaluated subsequent events occurring after September 30, 2026, through the date these unaudited condensed consolidated financial statements were issued.

 

Trading Symbol Change

 

On October 21, 2026, following processing by FINRA, the Company’s common stock began trading under the symbol “TRFA,” replacing the temporary symbol “GCAND” under which the common stock traded following the Second Reverse Split described in Note A.

 

Amendment and Restatement of Articles of Incorporation

 

On October 12, 2026, the Company’s Board of Directors approved an amendment and restatement of the Company’s Articles of Incorporation to revise its authorized capital structure and the rights, preferences, privileges, and limitations of its preferred securities. The amendment and restatement was also approved by the shareholders entitled to vote thereon.

 

The Amended and Restated Articles authorize 2,000,000,000 shares of common stock and 20,000,000 shares of preferred stock, each having a par value of $0.001 per share. Of the authorized preferred stock, 10,000,000 shares are designated Series A Preferred Stock and 1,000 shares are designated Series B Preferred Stock.

 

Under the Amended and Restated Articles, the Series A Preferred Stock is nonvoting and nonconvertible. The Series B Preferred Stock is nonconvertible and possesses voting rights representing at least 51% of the Company’s aggregate voting power, calculated on the fully diluted basis specified in the Amended and Restated Articles. The Series B

 

Preferred Stock is nonparticipating with respect to dividends and carries a liquidation preference of $1.00 per outstanding share.

 

Because the Amended and Restated Articles became effective subsequent to September 30, 2026, the Company’s capital structure and the rights of its outstanding securities as of September 30, 2026, are presented in accordance with the governing instruments then in effect.

 

F-20
 

 

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

The following discussion and analysis of the financial condition and results of operations of Trafalgar International, Inc. (formerly The Greater Cannabis Company, Inc.) (the “Company,” “Trafalgar,” “we,” “us,” or “our”) should be read in conjunction with the unaudited condensed consolidated financial statements and accompanying notes included elsewhere in this Quarterly Report on Form 10-Q, as well as the Company’s Annual Report on Form 10-K for the year ended December 31, 2025. This discussion contains forward-looking statements involving risks and uncertainties. Actual results may differ materially from those expressed or implied by such statements as a result of numerous factors, including the Company’s ability to obtain financing, execute its business strategy, complete potential acquisitions and strategic transactions, and maintain sufficient liquidity to fund its operations.

 

Company Overview and Business Transition

 

Trafalgar International, Inc. is a Florida corporation that historically operated under the name The Greater Cannabis Company, Inc. The Company has pursued business opportunities involving the development, licensing, and commercialization of cannabinoid-based technologies and related intellectual property.

 

From July 2018 through mid-2021, the Company’s principal business activities focused on developing and commercializing proprietary and licensed technologies for the transmucosal and transdermal delivery of cannabinoids. These activities included the development of an oral transmucosal patch platform intended to facilitate the absorption of active compounds through the buccal mucosa.

 

Although the Company achieved limited initial commercialization of this technology, historical management subsequently redirected its development activities toward other opportunities in the cannabinoid therapeutics sector.

 

On October 19, 2021, the Company entered into a licensing arrangement with Shaare Zedek Scientific Ltd. (“SZS”), the technology transfer organization associated with Shaare Zedek Medical Center in Jerusalem, Israel. The arrangement concerned certain cannabinoid-based therapeutic technologies being investigated for potential applications in neuropsychiatric and neurological disorders.

 

The licensed technology originated from research involving cannabinoid formulations and their potential therapeutic applications. The Company’s historical development strategy contemplated further research, clinical evaluation, and potential commercialization of the licensed technology, subject to applicable regulatory requirements, financing, and successful completion of development activities.

 

The Company has not generated material commercial revenues from these arrangements. The development and commercialization of cannabinoid-based therapeutic products remain subject to substantial scientific, regulatory, financial, and operational uncertainties.

 

June 2026 Change of Control and Business Transition

 

On June 29, 2026, the Company completed a series of transactions involving the acquisition of its outstanding preferred securities by Trafalgar Asset Management, LLC, a Delaware limited liability company owned and controlled by Porfirio Sanchez Talavera. The transactions resulted in a change in the Company’s principal shareholder and were accompanied by changes in management, corporate governance, and the Company’s strategic direction.

 

In connection with the change of control, the Company also entered into agreements providing for the cancellation, release, or extinguishment of certain historical indebtedness and other obligations. These transactions materially reduced the Company’s previously reported liabilities.

 

Following the change of control, the Company appointed a new executive management team, including Carlos Septién Michel, who was appointed Chief Operating Officer on July 29, 2026 and Chief Executive Officer effective September 18, 2026, Michelle Cervantes Vivanco as Chief Financial Officer, and Ernesto Gómez Berjón as Chief Growth Officer, with Porfirio Sanchez Talavera serving as Chairman of the Board. The new management team commenced evaluating the Company’s historical obligations, existing intellectual property interests, capitalization, and potential strategic opportunities as part of the transition to its revised business strategy.

 

1
 

 

On July 29, 2026, the Company filed Articles of Amendment with the Florida Department of State changing its name to Trafalgar International, Inc. and effecting a 1-for-5 reverse split of its common stock. The name change and reverse split became effective in the market on September 17, 2026, and the common stock began trading under the symbol “TRFA” on October 21, 2026. On October 12, 2026, the Company’s Board of Directors and majority shareholders approved the amendment and restatement of the Company’s Articles of Incorporation, which will become effective upon filing with the Florida Department of State, as described in Note K to the consolidated financial statements.

 

The Company intends to pursue this strategy through potential acquisitions, direct investments, joint ventures, licensing arrangements, strategic partnerships, and other business development opportunities.

 

Management’s objective is to identify transactions and operating opportunities that may provide a foundation for future revenue generation, business expansion, and long-term shareholder value.

 

The Company has not established a history of operating revenues under its revised business strategy. Its ability to implement that strategy will depend upon obtaining financing, identifying suitable opportunities, negotiating acceptable transaction terms, and successfully integrating or developing acquired businesses or assets.

 

The Company may also evaluate opportunities to retain, license, monetize, or otherwise realize value from its existing intellectual property portfolio.

 

Additional information concerning the Company’s historical operations, intellectual property arrangements, change of control, and capital structure is included in the notes to the accompanying consolidated financial statements.

 

Results of Operations

 

Comparison of the Three and Nine Months Ended September 30, 2026 and 2025.

 

Revenue

 

The Company reported no revenue during the three and nine months ended September 30, 2026 and 2025.

 

The absence of revenue reflects the Company’s limited commercialization activities and the transition of its business strategy following the June 2026 change of control.

 

Management expects that the timing and amount of future revenues, if any, will depend upon the successful implementation of the Company’s revised business strategy and the development or acquisition of revenue-producing operations.

 

Operating Expenses

 

Operating expenses for the three months ended September 30, 2026 were $90,335, compared with $37,412 for the corresponding period in 2025. Operating expenses for the nine months ended September 30, 2026 were $135,266, compared with $129,199 for the corresponding period in 2025, representing an increase of $6,067, or approximately 4.7%.

 

Historically, the Company’s operating expenses have consisted primarily of executive compensation, professional fees, administrative expenses, research and development expenditures, and other costs associated with maintaining its corporate operations and public reporting obligations.

 

2
 

 

The increase in operating expenses for both periods resulted primarily from professional services of $65,510 incurred during the third quarter of 2026, compared with no professional services in the corresponding periods of 2025. This increase was partially offset by lower officers’ compensation, which was $0 and $30,000 for the three months ended September 30, 2026 and 2025, respectively, and $30,000 and $90,000 for the nine months ended September 30, 2026 and 2025, respectively, following the resignation of the Company’s former Chief Executive Officer in connection with the change of control.

 

As the Company implements its revised business strategy, operating expenses may increase as a result of additional personnel, professional services, due diligence activities, transaction expenses, and costs associated with the development or acquisition of operating businesses.

 

Other Income and Expenses

 

The Company’s other income and expenses during the nine months ended September 30, 2026 were $622,933, compared with other expenses of $540,170 for the corresponding period in 2025. Other income for the 2026 period consisted of a gain on cancellation of debt of $621,450 and a gain on cancellation of Series A Preferred Stock of $1,483, and was materially affected by transactions involving the cancellation, settlement, and extinguishment of historical obligations in connection with the Company’s restructuring and June 2026 change of control.

 

In connection with these transactions, the Company entered into agreements providing for the cancellation and release of certain historical indebtedness and other obligations. These arrangements included obligations arising from prior financing transactions and related-party arrangements, as further described in the accompanying notes to the consolidated financial statements.

 

The financial effects of these transactions are reflected in the Company’s consolidated financial statements in accordance with applicable accounting principles, including the recognition and classification of extinguishment gains and equity-related adjustments, as appropriate.

 

The cancellation and settlement of historical obligations were nonrecurring in nature and did not generate operating cash inflows. Accordingly, management does not consider the financial statement effects of these transactions indicative of the Company’s ability to generate recurring operating revenue or sustainable operating earnings.

 

The Company’s future other income and expenses will depend upon its financing arrangements, capital structure, investment activities, and other transactions undertaken in connection with its revised business strategy.

 

Net Income (Loss)

 

For the three months ended September 30, 2026, the Company reported a net loss of $90,335, compared with a net loss of $36,099 for the corresponding period in 2025. For the nine months ended September 30, 2026, the Company reported net income of $487,667, compared with a net loss of $669,369 for the corresponding period in 2025.

 

The improvement in net results was primarily attributable to the recognition of nonrecurring income associated with the extinguishment of historical liabilities.

 

The Company’s reported net income did not result from revenue-generating operations and does not, by itself, indicate that the Company has achieved operating profitability or positive operating cash flow.

 

Management anticipates that future operating results will depend substantially upon the Company’s ability to secure additional capital and execute its revised business strategy.

 

3
 

 

Liquidity and Capital Resources

 

Financial Condition

 

As of September 30, 2026, the Company reported cash of $111, compared with $815 as of December 31, 2025.

 

The Company has historically financed its operations through related-party advances, debt financing, and the issuance of equity securities rather than cash generated from operating activities.

 

During 2026, the Company completed transactions resulting in the cancellation or extinguishment of certain historical liabilities, including related-party loans and third-party debt obligations.

 

Related-party loans payable decreased from $263,600 at December 31, 2025 to $85,624 at September 30, 2026. The related-party loans outstanding at December 31, 2025 were extinguished in connection with the change of control, and the balance at September 30, 2026 consists of loans made by Porfirio Sanchez Talavera during 2026 to fund the Company’s operating expenses.

 

Although the cancellation of historical obligations improved the Company’s reported financial position, the transactions did not generate operating cash or provide a continuing source of liquidity.

 

The Company continues to have limited cash resources and expects to require additional financing to fund its ongoing operations, satisfy current obligations, maintain its public company reporting requirements, and implement its business strategy.

 

Cash Flows

 

The following table summarizes the Company’s cash flows for the nine months ended September 30, 2026 and 2025:

 

   2026   2025 
Net cash used in operating activities  $(96,828)  $(36,013)
Net cash used in investing activities   —    — 
Net cash provided by financing activities  $96,124    — 
Net decrease in cash  $(704)  $(36,013)

 

Operating Activities

 

Net cash used in operating activities was $96,828 for the nine months ended September 30, 2026, compared with $36,013 for the corresponding period in 2025.

 

The increase in operating cash usage primarily reflects payment of professional services and other operating expenses during the 2026 period.

 

The Company’s operating activities have not generated sufficient cash to support its continuing obligations.

 

Investing Activities

 

The Company reported no material cash flows from investing activities during the nine months ended September 30, 2026 or 2025.

 

Future investing activities may include expenditures associated with acquisitions, strategic investments, technology development, and other business opportunities, depending upon the availability of financing.

 

4
 

 

Financing Activities

 

Net cash provided by financing activities was $96,124 for the nine months ended September 30, 2026, consisting of loans from Porfirio Sanchez Talavera, compared with no financing cash inflows during the corresponding period in 2025.

 

The Company expects that financing activities will remain an important source of liquidity until it establishes operations capable of generating sufficient positive cash flow.

 

Capital Requirements and Going Concern

 

The Company has limited liquidity, no established source of recurring operating revenue, and continuing cash requirements.

 

Management intends to seek additional capital through private placements of debt or equity securities, strategic investments, financing arrangements, and other transactions that may be available.

 

There can be no assurance that the Company will obtain sufficient financing, that financing will be available on commercially acceptable terms, or that management will successfully implement its business strategy.

 

Additional equity financing could result in substantial dilution to existing shareholders. Debt financing could impose additional payment obligations, restrictive covenants, or security interests in Company assets.

 

The Company’s ability to continue as a going concern depends upon obtaining adequate financing and ultimately establishing sustainable operations.

 

Management has determined that substantial doubt exists regarding the Company’s ability to continue as a going concern for one year following the issuance of the accompanying financial statements. See Note B to the consolidated financial statements.

 

Critical Accounting Policies and Estimates

 

The Company’s consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America.

 

Preparation of these financial statements requires management to make estimates, assumptions, and judgments that affect the reported amounts of assets, liabilities, revenues, expenses, and related disclosures.

 

Management considers accounting policies and estimates critical when they involve significant judgment or uncertainty and could materially affect the Company’s reported financial condition or results of operations.

 

Debt Extinguishments and Related-Party Transactions

 

The Company evaluates the cancellation, settlement, or extinguishment of financial obligations under the applicable provisions of U.S. GAAP.

 

The accounting treatment of debt extinguishments depends upon the contractual terms of the applicable obligations, the nature of the settlement, the consideration exchanged, and the relationship between the Company and the creditor.

 

Transactions involving shareholders or related parties may require different accounting treatment from settlements with unrelated creditors.

 

These judgments are particularly significant in evaluating the Company’s 2026 restructuring transactions.

 

5
 

 

Equity Instruments and Share-Based Compensation

 

The Company accounts for equity instruments issued in exchange for employee and nonemployee services in accordance with ASC Topic 718, Compensation—Stock Compensation.

 

Determining the appropriate recognition and measurement of share-based compensation may require management to evaluate the fair value of the securities issued, the terms of the applicable arrangements, and the period over which services are rendered.

 

Income Taxes

 

The Company accounts for income taxes under ASC Topic 740, Income Taxes.

 

Management evaluates the realizability of deferred tax assets, including net operating loss carryforwards, based upon available evidence concerning future taxable income and applicable statutory limitations.

 

The Company’s historical losses and changes in ownership are significant considerations in evaluating its deferred tax assets and related valuation allowances.

 

Intangible Assets and Impairment

 

The Company evaluates intangible assets and other long-lived assets for impairment in accordance with applicable accounting guidance.

 

These evaluations may require judgments regarding the commercial viability of licensed technologies, expected future cash flows, development requirements, and other factors affecting the recoverability of carrying values.

 

Actual results may differ materially from management’s estimates and assumptions.

 

Off-Balance Sheet Arrangements

 

The Company has not entered into off-balance sheet arrangements that have, or are reasonably likely to have, a material current or future effect on its financial condition, results of operations, liquidity, capital expenditures, or capital resources.

 

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

The Company is a smaller reporting company, as defined in Rule 12b-2 under the Securities Exchange Act of 1934, as amended, and is not required to provide the information otherwise required by this Item.

 

ITEM 4. CONTROLS AND PROCEDURES

 

Evaluation of Disclosure Controls and Procedures

 

The Company’s management, with the participation and supervision of its Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of the Company’s disclosure controls and procedures as of September 30, 2026, pursuant to Rule 13a-15(b) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”).

 

Disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, are designed to provide reasonable assurance that information required to be disclosed by the Company in reports filed or submitted under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission.

 

6
 

 

Disclosure controls and procedures are also designed to provide reasonable assurance that such information is accumulated and communicated to the Company’s management, including its principal executive and principal financial officers, as appropriate, to allow timely decisions regarding required disclosures.

 

Based upon this evaluation, management concluded that the Company’s disclosure controls and procedures were not effective as of September 30, 2026.

 

The determination reflects material weaknesses in the Company’s internal control environment, including limitations associated with its historical organizational structure, limited accounting and financial reporting resources, and insufficient segregation of duties.

 

The Company previously disclosed material weaknesses in its internal control over financial reporting in its Annual Report on Form 10-K for the year ended December 31, 2025. Management continues to evaluate these weaknesses and the measures necessary to improve the Company’s disclosure controls and financial reporting processes.

 

Remediation of Material Weaknesses

 

Following the Company’s June 2026 change of control and subsequent management transition, management commenced a review of the Company’s existing accounting, financial reporting, and disclosure procedures to identify deficiencies and evaluate appropriate corrective measures.

 

Management’s remediation objectives include strengthening oversight of financial reporting, improving documentation and review procedures, enhancing segregation of duties where practicable, and utilizing qualified accounting and financial reporting professionals to support the preparation and review of the Company’s periodic reports.

 

The Company’s ability to implement these measures depends upon its available financial and personnel resources. Management has not concluded that the previously identified material weaknesses have been fully remediated.

 

Management will continue to evaluate the effectiveness of its disclosure controls and procedures and internal control over financial reporting. Until sufficient corrective measures have been implemented and their effectiveness demonstrated, the identified material weaknesses may continue to adversely affect the Company’s financial reporting processes.

 

Changes in Internal Control Over Financial Reporting

 

During the quarter ended September 30, 2026, there were no changes in the Company’s internal control over financial reporting, as defined in Rule 13a-15(f) under the Exchange Act, that materially affected, or were reasonably likely to materially affect, the Company’s internal control over financial reporting.

 

7
 

 

PART II- OTHER INFORMATION

 

ITEM 1. LEGAL PROCEEDINGS

 

There are no material pending legal proceedings to which the Company or any of its subsidiaries is a party or to which any of their respective properties is subject that are required to be disclosed pursuant to Item 103 of Regulation S-K.

 

ITEM 1A. RISK FACTORS

 

The Company is a smaller reporting company, as defined in Rule 12b-2 under the Securities Exchange Act of 1934, as amended, and is not required to provide the information otherwise required by this Item.

 

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

 

The Company did not sell any equity securities during the three months ended September 30, 2026 that were not registered under the Securities Act of 1933, as amended, and that have not otherwise been reported in a Current Report on Form 8-K or another report filed with the Securities and Exchange Commission.

 

The Company did not repurchase any of its equity securities during the three months ended September 30, 2026.

 

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

 

None.

 

ITEM 4. MINE SAFETY DISCLOSURES

 

Not applicable.

 

ITEM 5. OTHER INFORMATION

 

During the three months ended September 30, 2026, no director or officer of the Company adopted, modified, or terminated a contract, instruction, or written plan for the purchase or sale of Company securities intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended, or any non-Rule 10b5-1 trading arrangement, as such terms are defined in Item 408(c) of Regulation S-K. There is no other information required to be disclosed under this Item that has not previously been reported.

 

ITEM 6. EXHIBITS

 

Exhibit No.   Description
31.1   Certification of Carlos Septién Michel, Chief Executive Officer (Principal Executive Officer), pursuant to Rule 13a-14(a) or Rule 15d-14(a) under the Securities Exchange Act of 1934, as amended (filed herewith).
31.2   Certification of Michelle Cervantes Vivanco, Chief Financial Officer (Principal Financial Officer), pursuant to Rule 13a-14(a) or Rule 15d-14(a) under the Securities Exchange Act of 1934, as amended (filed herewith).
32.1   Joint Certification of Carlos Septién Michel, Chief Executive Officer (Principal Executive Officer), and Michelle Cervantes Vivanco, Chief Financial Officer (Principal Financial Officer), pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (furnished herewith).
101.INS   Inline XBRL Instance Document
101.SCH   Inline XBRL Taxonomy Extension Schema Document
101.CAL   Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF   Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB   Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE   Inline XBRL Taxonomy Extension Presentation Linkbase Document
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

8
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  TRAFALGAR INTERNATIONAL, INC.
   
November 19, 2026 /s/ Carlos Septién Michel
  Chief Executive Officer
  (Principal executive officer)

 

9

 

Keep reading